EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access

Group B Streptococcus vaccine: state of the art

Annalisa Nuccitelli, C Daniela Rinaudo, Domenico Maione

Therapeutic Advances in Vaccines · 2015-05 · 3 (3) · 76-90

DOI: 10.1177/2051013615579869 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Therapeutic Advances in Vaccines, online erschienen am 14.04.2015. Verfasst von Annalisa Nuccitelli und 2 weiteren Autor:innen. Beteiligte Einrichtung: Novartis Vaccines, Siena, Italy. Die Arbeit wurde bisher 108-mal zitiert (Crossref) und nennt 100 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Group B Streptococcus (GBS) is cause of neonatal invasive diseases as well as of severe infections in the elderly and immune-compromised patients. Despite significant advances in the prevention and treatment of neonatal disease, sepsis and meningitis caused by GBS still represent a significant public health care concern globally and additional prevention and therapeutic strategies against infection are highly desirable. The introduction of national recommended guidelines in several countries to screen pregnant women for GBS carriage and the use of antibiotics during delivery significantly reduced disease occurring within the first hours of life (early-onset disease), but it has had no effect on the late-onset diseases occurring after the first week and is not feasible in most countries. Availability of an effective vaccine against GBS would provide an effective means of controlling GBS disease. This review provides an overview of the burden of invasive disease caused by GBS in infants and adults, and highlights the strategies for the development of an effective vaccine against GBS infections.

Schlagwörter

Stichwörter der Autor:innen

CPS-based conjugate vaccineearly-onset diseasegroup B Streptococcuslate-onset diseaseprotein-based vaccine

Autor:innen und Institutionen

  • Novartis Vaccines, Siena, Italy.
  • Novartis Vaccines and Diagnostics, via Fiorentina 1, 53100 Siena, Italy.

Zitieren

APA

Nuccitelli, A., Rinaudo, C. D., & Maione, D. (2015). Group B Streptococcus vaccine: state of the art. Therapeutic Advances in Vaccines, 3(3), 76-90. https://doi.org/10.1177/2051013615579869

Vancouver

Nuccitelli A, Rinaudo CD, Maione D. Group B Streptococcus vaccine: state of the art. Therapeutic Advances in Vaccines. 2015;3(3):76-90. doi:10.1177/2051013615579869

BibTeX
@article{Nuccitelli2015,
  author = {Nuccitelli, Annalisa and Rinaudo, C Daniela and Maione, Domenico},
  title = {Group B Streptococcus vaccine: state of the art},
  journal = {Therapeutic Advances in Vaccines},
  year = {2015},
  volume = {3},
  number = {3},
  pages = {76--90},
  doi = {10.1177/2051013615579869}
}
Kostenlos starten →